Powerful Medical Receives €40 Million IPCEI Grant — read the full story

Powerful Medical
11. November 2024
3 min to read

Deep-learning Assisted ECG-based Emergent Cathlab Activation: First Prospective Implementation of a Smartphone-based System

Deep-learning Assisted ECG-based Emergent Cathlab Activation

Overview

In its first prospective performance evaluation, the PMcardio STEMI AI ECG Model outperformed standard ECG machine readings, detecting high-risk coronary blockage with 95.7% sensitivity vs. 47.8%. By correctly flagging 15 initially missed patients, the AI model demonstrated its potential to strengthen triage accuracy and accelerate life-saving decisions.

Published In: Circulation (AHA Journals) – presented at the American Heart Association (AHA) 2024 Scientific Sessions
Presented Date: November 11, 2024

Background

Standard ST-segment elevation myocardial infarction (STEMI) pathways misidentify up to 50% of patients with an acutely occluded culprit coronary artery (OMI) with false positive emergent cathlab activations in up to 35% of cases. Recently, an artificial intelligence (AI) electrocardiogram (ECG) model outperformed standard of care in detecting OMI in international retrospective cohorts.

We sought to prospectively evaluate the rule-in performance of an AI ECG model in a large tertiary care STEMI network compared to ECG machine readings of STEMI and AI-assisted emergency physicians.

Methods

An AI model trained to detect acute coronary occlusion regardless of ST elevation was implemented using smartphones in a tertiary care STEMI network consisting of 1 hub hospital, 1 spoke center, and 2 emergency medical service crews (EMS) (Fig 1A). Outcomes of all patients presenting with atraumatic chest pain during a 10-week period between January and March 2024 were adjudicated using ECG, laboratory, and angiographic chart review and classified based on the presence of OMI.

Results

A total of 731 consecutive patients (68% male) with atraumatic chest pain were included; 142 patients were hospitalized of whom 23 (16%) met the primary outcome of OMI. The AI model showed a significantly higher sensitivity detecting OMI as compared to ECG machine (95.7% vs. 47.8%, p<0.001, Fig 1B) at comparable specificity (95% vs. 96%, respectively) with overall superior predictive accuracy (Chi-squared=8.1; p=0.004). The AI model correctly identified 15 cases that the ECG machine misclassified (80% were false negatives by ECG machine). All AI false positives were patients post recent myocardial infarction or angioplasty. Sensitivity of AI-assisted emergency physicians interpreting OMI was 78.2% indicating potential instances of AI underutilization.

Conclusion

This first prospective performance evaluation in a large all-comer atraumatic chest pain cohort indicates high accuracy of unbiased, AI-powered ECG detecting acute coronary occlusion. The findings suggest its potential to improve ACS patient outcomes through timely referral for invasive management in a real-world clinical setting.


Authors: Robert Herman, MD, Rinaldo Lauwers, MD, David Pletnickx, MA, Harvey Meyers, MD, Stephen Smith, MD, Timea Kisova, MD, BSC, Anthony Demolder, MD, MSc, PhD, Peter Herman, Student, Radka Grendova, MA, Monika Beles, MS, Leor Perl, BSC, MD, Olivier Nelis, BSC, Emanuele Barbato, MD, Jozef Bartunek, MD, Dan Schelfaut, MD

Author-Logo_PM
Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.

About PMcardio

PMcardio is a CE-certified AI that reads ECGs and offers a complex assessment of 49 cardiac conditions. Clinically validated in 15+ studies and trusted by over 100,000 clinicians, it delivers rapid, expert‑level interpretations, empowering emergency physicians, GPs, nurses, paramedics, and cardiologists to act with confidence at the point of care. Available for Individuals and Organizations.

About Powerful Medical

Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.

Share this article

Relevant Publications

Door-to-Balloon Time Outperforms ST-Segment Elevation inPredicting the STEMI vs. NSTEMI Final Diagnosis

In a two-center registry study, investigators compared traditional STEMI/NSTEMI classification with angiographic and interventional diagnoses. Although guideline-defined ST-elevation criteria underpin quality metrics and reperfusion standards, they often fail to capture acute coronary occlusion myocardial infarction (OMI). This discordance has led to proposals for an OMI/Non-OMI paradigm, grounded in pathophysiology rather than ECG morphology. The study examined whether door-to-balloon time < 120 min aligns more closely with final cardiologist adjudication than either ST-segment elevation on ECG or angiographic evidence of TIMI 0–1 flow.

Hyperacute T Waves are specific for Occlusion Myocardial Infarction, even without diagnostic ST elevation

This study aimed to derive and validate a quantitative definition of hyperacute T waves (HATW) by developing the HATW score and evaluating its diagnostic accuracy for identifying acute coronary occlusion in patients with possible ACS but without STEMI criteria.

Join over 100,000 healthcare professionals who are already taking advantage of AI